Marasmus

Summary

Marasmus (MONDO:0006848) is a disease and 10 clinical trials. Top therapeutic interventions include amoxicillin, albendazole, and cefdinir. A subtype of protein-energy malnutrition — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	marasmus
Mondo ID	MONDO:0006848
EFO	EFO:1001033
DOID	DOID:12328
ICD-10-CM	E41
SNOMED CT	29740003
UMLS	C0086588
MedGen	39251
MedDRA	10026820
Is cancer (heuristic)	no

Also known as: nutritional marasmus

Disease family

This is a subtype of protein-energy malnutrition. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › nutritional disorder › nutritional deficiency disease › protein-energy malnutrition › marasmus

Related subtypes (1): kwashiorkor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cannabinol	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00069134	Not specified	COMPLETED	Study of Antioxidants and Oxidants in Malnourished Children
NCT01000298	Not specified	COMPLETED	Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
NCT01395381	Not specified	WITHDRAWN	Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition
NCT01529125	Not specified	COMPLETED	Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
NCT01790815	Not specified	COMPLETED	Mothers Understand And Can do it - Mid Upper Arm Circumference Screening for Malnutrition Performed by Mothers
NCT02053857	Not specified	COMPLETED	Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition
NCT02413905	Not specified	COMPLETED	Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition
NCT02751476	Not specified	UNKNOWN	Effectiveness of Safe Drinking Water in Treatment of Severe Acute Malnutrition (Pakistan)
NCT05009823	Not specified	COMPLETED	Dietary Rehabilitation in Severely Acutely Malnourished Children
NCT05020847	Not specified	COMPLETED	Effectiveness of Alternative Diets During the Stabilization Phase on Children With Complicated SAM

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AMOXICILLIN	4	2
ALBENDAZOLE	4	1
CEFDINIR	4	1